Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: MYL075
MIFTS: 51

Myelodysplastic/myeloproliferative Neoplasm

Categories: Blood diseases, Cancer diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Myelodysplastic/myeloproliferative Neoplasm

About this section

MalaCards integrated aliases for Myelodysplastic/myeloproliferative Neoplasm:

Name: Myelodysplastic/myeloproliferative Neoplasm 12 20 15 37 17
Myelodysplastic/myeloproliferative Disease 20 58
Myeloproliferative/myelodysplastic Syndromes 12
Myelodysplastic/myeloproliferative Neoplasms 36
Myelodysplastic-Myeloproliferative Diseases 44
Myelodysplastic Myeloproliferative Disease 12
Myelodysplastic Myeloproliferative Cancer 12

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Blood diseases
See all MalaCards categories (disease lists)
ICD10: 32
Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:4972
KEGG 36 H02410
MeSH 44 D054437
NCIt 50 C27262
SNOMED-CT 67 445738007
ICD10 32 C94.6
MESH via Orphanet 45 D054437
UMLS via Orphanet 72 C1301355
Orphanet 58 ORPHA98275
UMLS 71 C1301355
Sources

Summaries for Myelodysplastic/myeloproliferative Neoplasm

About this section
GARD : 20 Myelodysplastic/myeloproliferative diseases are a group of diseases of the blood and bone marrow in which the bone marrow makes too many white blood cells. These disease have features of both myelodysplastic syndromes and myeloproliferative disorders. In myelodysplastic diseases, the blood stem cells do not mature into healthy red blood cells, white blood cells, or platelets and as a result, there are fewer of these healthy cells. In myeloproliferative diseases, a greater than normal number of blood stem cells develop into one or more types of blood cells and the total number of blood cells slowly increases. The 3 main types of myelodysplastic/myeloproliferative diseases include chronic myelomonocytic leukemia (CMML); juvenile myelomonocytic leukemia (JMML); and atypical chronic myelogenous leukemia (aCML). When a myelodysplastic/myeloproliferative disease does not match any of these types, it is called myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-UC). Symptoms of CMML and JMML may include fever, feeling tired and weight loss. Symptoms of aCML may include easy bruising or bleeding and feeling tired or weak. Myelodysplastic/myeloproliferative diseases may progress to acute leukemia. There are different types of treatment for individuals with one of these diseases, which may include chemotherapy, another drug therapy, stem cell transplant and/or supportive care.

MalaCards based summary : Myelodysplastic/myeloproliferative Neoplasm, also known as myelodysplastic/myeloproliferative disease, is related to thrombocytosis and atypical chronic myeloid leukemia. An important gene associated with Myelodysplastic/myeloproliferative Neoplasm is NRAS (NRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are Ras signaling pathway and ERK Signaling. The drugs Mercaptopurine and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, bone and myeloid, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A myeloid neoplasm that results in the overproduction of white blood cells.

KEGG : 36 Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are hybrid group of chronic myeloid neoplasms combining features of both myelodysplastic (MDS) [DS:H01481] and myeloproliferative neoplasms (MPN). This group includes chronic myelomonocytic leukemia (CMML), its pediatric counterpart juvenile myelomonocytic leukemia (JMML), MDS/MPN with ringed sideroblasts and thrombocytosis (MDS/MPN-RS-T), atypical BCR-ABL1 negative chronic myeloid leukemia (aCML) and MDS/MPN- unclassifiable (MDS/MPN-u). Somatic mutations observed in MDS/MPN fall in 4 major categories, including signaling, splicing, epigenetic, and transcription gene mutations.

Sources

Related Diseases for Myelodysplastic/myeloproliferative Neoplasm

About this section

Diseases related to Myelodysplastic/myeloproliferative Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 144)
# Related Disease Score Top Affiliating Genes
1 thrombocytosis 31.0 TET2 JAK2 CSF2 ASXL1
2 atypical chronic myeloid leukemia 30.6 U2AF1L4 U2AF1 TET2 SRSF2 SETBP1 PDGFRB
3 refractory anemia 30.5 TET2 JAK2 ASXL1
4 monocytic leukemia 30.4 KMT2A FLT3 CSF2
5 myeloid sarcoma 30.4 U2AF1 KMT2A FLT3
6 juvenile myelomonocytic leukemia 30.3 U2AF1 TET2 SETBP1 PTPN11 PDGFRB NRAS
7 thrombocytopenia 30.2 U2AF1 PTPN11 JAK2 FLT3 DNMT3A CSF2
8 hypereosinophilic syndrome 30.1 PDGFRB JAK2 CSF2 ABL1
9 neutropenia 30.1 PTPN11 JAK2 FLT3 CSF3R CSF2
10 acute megakaryocytic leukemia 30.0 U2AF1 KMT2A JAK2 FLT3 CSF2
11 mastocytosis 30.0 TET2 SRSF2 PDGFRB JAK2 FLT3 ASXL1
12 deficiency anemia 30.0 U2AF1 NRAS JAK2 FLT3 CSF2
13 polycythemia vera 29.9 U2AF1 TET2 PDGFRB JAK2 DNMT3A CSF2
14 acute promyelocytic leukemia 29.9 NRAS KMT2A HRAS FLT3 CSF3R CSF2
15 myeloproliferative neoplasm 29.9 U2AF1 TET2 PTPN11 PDGFRB NRAS NF1
16 essential thrombocythemia 29.8 U2AF1 TET2 PTPN11 JAK2 CSF2 ASXL1
17 aplastic anemia 29.7 U2AF1 TET2 NRAS FLT3 CSF3R CSF2
18 systemic mastocytosis 29.5 TET2 SRSF2 PTPN11 PDGFRB NRAS JAK2
19 leukemia, acute lymphoblastic 29.4 U2AF1 PTPN11 KMT2A JAK2 HRAS FLT3
20 myelofibrosis 29.3 U2AF1 TET2 SRSF2 SETBP1 PDGFRB JAK2
21 myeloid leukemia 29.2 U2AF1 TET2 PTPN11 NRAS KMT2A JAK2
22 leukemia 29.1 U2AF1 TET2 PTPN11 NRAS NF1 KMT2A
23 leukemia, chronic myeloid 28.6 U2AF1 SETBP1 PTPN11 PDGFRB NRAS NF1
24 myelodysplastic syndrome 28.6 U2AF1 TET2 SRSF2 SETBP1 PTPN11 PDGFRB
25 chronic myelomonocytic leukemia 28.3 U2AF1 TET2 SRSF2 SETBP1 PTPN11 PDGFRB
26 leukemia, acute myeloid 28.2 U2AF1L4 U2AF1 TET2 SRSF2 SETBP1 PTPN11
27 unclassified myelodysplastic/myeloproliferative disease 11.3
28 rubinstein taybi like syndrome 10.4 KMT2A ASXL1
29 keratosis pilaris atrophicans faciei 10.4 PTPN11 NF1
30 meningeal melanomatosis 10.4 NRAS HRAS
31 b-lymphoblastic leukemia/lymphoma with bcr-abl1 10.4 KMT2A ABL1
32 b-lymphoblastic leukemia/lymphoma, bcr-abl1-like 10.4 JAK2 ABL1
33 malignant anus melanoma 10.3 NRAS HRAS
34 conjunctival nevus 10.3 NRAS HRAS
35 cytogenetically normal acute myeloid leukemia 10.3 KMT2A FLT3
36 malignant dermis tumor 10.3 NRAS HRAS
37 central nervous system melanocytic neoplasm 10.3 NRAS HRAS
38 acneiform dermatitis 10.3 NRAS HRAS
39 malignant skin fibrous histiocytoma 10.3 NRAS HRAS
40 testicular spermatocytic seminoma 10.3 PTPN11 HRAS DNMT3A
41 vulvar melanoma 10.3 NRAS NF1 HRAS
42 mental retardation, autosomal dominant 29 10.3 SETBP1 ABL1
43 malignant spindle cell melanoma 10.3 NRAS NF1 HRAS
44 central nervous system leukemia 10.3 KMT2A ABL1
45 pulsating exophthalmos 10.3 PDGFRB NF1
46 mixed phenotype acute leukemia 10.3 U2AF1 SETBP1 KMT2A DNMT3A
47 neurofibromatosis-noonan syndrome 10.3 PTPN11 NF1 HRAS
48 polycythemia 10.3
49 acute monoblastic leukemia 10.3 NF1 KMT2A CSF2
50 leukemia, acute monocytic 10.3 U2AF1 KMT2A FLT3

Graphical network of the top 20 diseases related to Myelodysplastic/myeloproliferative Neoplasm:



Diseases related to Myelodysplastic/myeloproliferative Neoplasm
Sources

Symptoms & Phenotypes for Myelodysplastic/myeloproliferative Neoplasm

About this section

GenomeRNAi Phenotypes related to Myelodysplastic/myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

26 (show all 14)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.38 HRAS
2 Decreased viability GR00055-A-2 10.38 HRAS
3 Decreased viability GR00106-A-0 10.38 U2AF1
4 Decreased viability GR00173-A 10.38 FLT3
5 Decreased viability GR00221-A-1 10.38 ABL1 ETNK1 FLT3 HRAS NF1 NRAS
6 Decreased viability GR00221-A-2 10.38 ABL1 ETNK1 HRAS JAK2 NF1
7 Decreased viability GR00221-A-3 10.38 ABL1 ETNK1 HRAS NRAS PDGFRB
8 Decreased viability GR00221-A-4 10.38 ETNK1 FLT3 NF1 PDGFRB
9 Decreased viability GR00249-S 10.38 CSF2 CSF3R NF1
10 Decreased viability GR00342-S-1 10.38 ABL1 ETNK1 PDGFRB
11 Decreased viability GR00342-S-2 10.38 ABL1
12 Decreased viability GR00342-S-3 10.38 ABL1
13 Decreased viability GR00386-A-1 10.38 LUC7L2 NF1 SRSF2
14 Decreased viability GR00402-S-2 10.38 DNMT3A KMT2A SRSF2 U2AF1 U2AF1L4

MGI Mouse Phenotypes related to Myelodysplastic/myeloproliferative Neoplasm:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.38 ABL1 ASXL1 CSF2 CSF3R DNMT3A FLT3
2 behavior/neurological MP:0005386 10.37 ABL1 ASXL1 CSF2 CSF3R DNMT3A HRAS
3 cardiovascular system MP:0005385 10.33 ABL1 CSF2 HRAS JAK2 KMT2A NF1
4 hematopoietic system MP:0005397 10.33 ABL1 ASXL1 CSF2 CSF3R DNMT3A ETNK1
5 endocrine/exocrine gland MP:0005379 10.31 ABL1 ASXL1 CSF2 DNMT3A FLT3 HRAS
6 growth/size/body region MP:0005378 10.29 ABL1 ASXL1 CSF2 DNMT3A FLT3 HRAS
7 homeostasis/metabolism MP:0005376 10.25 ABL1 ASXL1 CSF2 DNMT3A FLT3 HRAS
8 immune system MP:0005387 10.25 ABL1 ASXL1 CSF2 CSF3R ETNK1 FLT3
9 mortality/aging MP:0010768 10.22 ABL1 ASXL1 CSF2 CSF3R DNMT3A FLT3
10 craniofacial MP:0005382 10.18 ABL1 ASXL1 CSF2 HRAS KMT2A NF1
11 embryo MP:0005380 10.16 ABL1 CSF2 DNMT3A JAK2 KMT2A NF1
12 liver/biliary system MP:0005370 9.97 ABL1 ASXL1 JAK2 KMT2A NF1 NRAS
13 muscle MP:0005369 9.86 ABL1 DNMT3A HRAS KMT2A NF1 PDGFRB
14 neoplasm MP:0002006 9.85 ASXL1 CSF2 FLT3 HRAS JAK2 KMT2A
15 normal MP:0002873 9.61 ABL1 HRAS JAK2 KMT2A NF1 NRAS
16 skeleton MP:0005390 9.44 ABL1 ASXL1 CSF2 DNMT3A ETNK1 FLT3
Sources

Drugs & Therapeutics for Myelodysplastic/myeloproliferative Neoplasm

About this section

Drugs for Myelodysplastic/myeloproliferative Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 316)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mercaptopurine Approved Phase 3 50-44-2 667490
2
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
3
Etoposide Approved Phase 3 33419-42-0 36462
4
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
5
Idarubicin Approved Phase 3 58957-92-9 42890
6
Thioguanine Approved Phase 3 154-42-7 2723601
7
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
8
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
9
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
10
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
11
Amitriptyline Approved Phase 3 50-48-6 2160
12
Baclofen Approved Phase 3 1134-47-0 2284
13
Perphenazine Approved Phase 3 58-39-9 4748
14
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
15
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
16
Moxifloxacin Approved, Investigational Phase 3 151096-09-2, 354812-41-2 152946
17
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
18
Polyestradiol phosphate Approved Phase 3 28014-46-2
19
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
20 Neurotransmitter Agents Phase 3
21 Folic Acid Antagonists Phase 3
22 Antiviral Agents Phase 3
23 Etoposide phosphate Phase 3
24 Antidepressive Agents Phase 3
25 Psychotropic Drugs Phase 3
26
asparaginase Phase 3
27 Hydrocortisone hemisuccinate Phase 3
28 Hydrocortisone-17-butyrate Phase 3
29 Hydrocortisone 17-butyrate 21-propionate Phase 3
30 Ophthalmic Solutions Phase 3
31 GABA Agonists Phase 3
32 Anesthetics, Dissociative Phase 3
33 Antipsychotic Agents Phase 3
34 Excitatory Amino Acid Antagonists Phase 3
35 Adrenergic Agents Phase 3
36 Amitriptyline, perphenazine drug combination Phase 3
37 Antidepressive Agents, Tricyclic Phase 3
38 Contraceptives, Oral Phase 3
39 Contraceptive Agents Phase 3
40 Estradiol 3-benzoate Phase 3
41 Estradiol 17 beta-cypionate Phase 3
42 Contraceptives, Oral, Combined Phase 3
43 Norgestimate, ethinyl estradiol drug combination Phase 3
44
Megestrol acetate Approved, Investigational, Vet_approved Phase 2 595-33-5 11683
45
Histamine Approved, Investigational Phase 2 51-45-6, 75614-87-8 774
46
Cyproheptadine Approved Phase 2 129-03-3 2913
47
Ganciclovir Approved, Investigational Phase 2 82410-32-0 3454
48
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
49
Etanercept Approved, Investigational Phase 2 185243-69-0
50
Voriconazole Approved Phase 2 137234-62-9 71616

Interventional clinical trials:

(show top 50) (show all 223)
# Name Status NCT ID Phase Drugs
1 Prospective Study of the Diagnosis and Treatment of Myelodysplastic Syndromes (MDS) in Childhood Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
2 Intravenous Low-Dose Decitabine Versus Supportive Care in Elderly Patients With Primary Myelodysplastic Syndrome (MDS) (>10% Blasts or High-Risk Cytogenetics), Secondary MDS or Chronic Myelomonocytic Leukemia (CMML) Who Are Not Eligible for Intensive Therapy: An EORTC-German MDS Study Group Randomized Phase III Study Unknown status NCT00043134 Phase 3 decitabine
3 Phase III Trial of T Lymphocyte Depletion by Elutriation and CD34 Add-Back for Allogeneic Bone Marrow Transplantation Completed NCT00265837 Phase 3
4 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
5 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
6 A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
7 A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201) Completed NCT00075816 Phase 3
8 Protocol for Patients With High Risk (Resistant, Refractory, Relapsed or Adverse Cytogenetic) AML Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
9 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
10 Treatment of Children With Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD): A Phase III Group-Wide Study Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
11 A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
12 A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplant Conditioning in Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Completed NCT00322101 Phase 3 cyclophosphamide;mycophenolate mofetil;busulfan;cyclosporine;fludarabine phosphate;tacrolimus;methotrexate
13 A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
14 Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
15 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
16 HSCT-CHESS to Enhance Hematopoietic Transplant Recovery Completed NCT00782145 Phase 3
17 The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study Completed NCT00516503 Phase 3 baclofen/amitriptyline/ketamine gel
18 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
19 Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
20 A Phase II Trial of Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Unrelated Donors in Patients With Advanced Hematologic Malignancies and Hematological Disorders Unknown status NCT00544115 Phase 2 busulfan;cyclophosphamide;cyclosporine;etoposide;fludarabine phosphate;melphalan;methotrexate;mycophenolate mofetil;sirolimus;tacrolimus
21 Transplantation Using Umbilical Cord And Placental Blood Unknown status NCT00008164 Phase 2
22 A Multiinstitutional Trial To Evaluate The Prophylactic Use Of NASA-Developed Light Emitting Diodes For The Prevention Of Oral Mucositis In Bone Marrow Transplant Patients Unknown status NCT00036712 Phase 2
23 The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
24 A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial Completed NCT00105001 Phase 2 Fludarabine Phosphate;Tacrolimus;Mycophenolate Mofetil;Sirolimus
25 Phase II Study of Intravenous Ganciclovir Followed by Oral Ganciclovir in the Treatment of Reactivation of CMV Following Bone Marrow Transplant Completed NCT00530218 Phase 2 Ganciclovir
26 Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation With a Conditioning Regimen of Targeted Busulfan, Cyclophosphamide, and Thymoglobulin Completed NCT00611351 Phase 2 busulfan;cyclophosphamide;mycophenolate mofetil;tacrolimus
27 A Phase 2 Study of WEE1 Inhibition With AZD1775 Alone or Combined With Cytarabine in Patients With Advanced Acute Myeloid Leukemia and Myelodysplastic Syndrome Completed NCT02666950 Phase 2 Cytarabine;WEE1 Inhibitor AZD1775
28 A Phase II Study to Evaluate Low-Dose Alemtuzumab as a Glucocorticoid-Sparing Agent for Initial Systemic Treatment of Acute Graft-Versus-Host Disease Completed NCT00410657 Phase 2 methylprednisolone;prednisone
29 Conditioning For Hematopoietic Cell Transplantation With Fludarabine Plus Targeted IV Busulfan and GVHD Prophylaxis With Thymoglobulin, Tacrolimus and Methotrexate in Patients With Myeloid Malignancies Completed NCT00346359 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
30 A Phase I/II Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients With Hematologic Malignancies Using Busulfan, Fludarabine and Total Body Irradiation Completed NCT00245037 Phase 1, Phase 2 busulfan;cyclosporine;fludarabine phosphate;mycophenolate mofetil;Granulocyte colony-stimulating factor (G-CSF);Phenytoin;Methotrexate
31 Therapy of Early Stage Myelodysplastic Syndrome (MDS) With ATG and Etanercept Completed NCT00217386 Phase 2
32 Phase II Clinical Trial Incorporating Alemtuzumab (Campath-1H) in Combination With FK506 and Methylprednisolone for Treatment of Severe Acute Graft vs Host Disease Completed NCT00109993 Phase 2 methylprednisolone;tacrolimus
33 A Phase II Study of the Combination of Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-Versus-Host Disease Completed NCT00096096 Phase 2 mycophenolate mofetil;tacrolimus
34 Therapy of Advanced Stage Myelodysplastic Syndrome (MDS) With Arsenic Trioxide Given in Combination With Etanercept: A Phase I/II Study Completed NCT00093366 Phase 1, Phase 2 arsenic trioxide
35 A Phase I/II Study of Sirolimus in Addition to Tacrolimus and Methotrexate for the Prevention of Acute-Graft-Versus-Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation From Unrelated Donors Completed NCT00089037 Phase 1, Phase 2 methotrexate;sirolimus;tacrolimus
36 A Phase II Study of VNP40101M For Patients With Acute Myelogenous Leukemia Or High-Risk Myelodysplasia Completed NCT00083187 Phase 2 hydroxyurea;laromustine
37 A Phase I-II Safety, Tolerability And Pharmacokinetic Study Of Ravuconazole For Prophylaxis Of Invasive Fungal Infections In Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT00064311 Phase 1, Phase 2 ravuconazole
38 An Open-Label, Intravenous To Oral Switch, Multiple Dose, Multi-Center Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Voriconazole In Hospitalized Children Aged 2 - <12 Years Who Require Treatment For The Prevention Of Systemic Fungal Infection Completed NCT00066599 Phase 2 voriconazole
39 A Phase I/II Study of Immunologically Engineered rhG-CSF Mobilized Peripheral Blood Stem Cells (PBSC) for Allogeneic Transplant From HLA Identical, Related Donors for Treatment of Myeloid Malignancies Completed NCT00049634 Phase 1, Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate
40 Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial Completed NCT00040846 Phase 2 fludarabine phosphate;mycophenolate mofetil;cyclosporine
41 Ex Vivo Expanded Megakaryocytes for Supportive Care of Breast Cancer Patients: A Phase I/II Study Completed NCT00006225 Phase 1, Phase 2
42 Allogeneic Bone Marrow Transplantation for Hematologic Malignancies: A Treatment Approach Based on Risk of Relapse and Toxicity Completed NCT00005797 Phase 2 busulfan;Cyclophosphamide;VP-16
43 Autologous Bone Marrow Transplantation for Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome - A Phase II Pilot Study Completed NCT00004899 Phase 2 busulfan;etoposide
44 Unrelated Bone Marrow Transplantation With Cyclophosphamide and Total Body Irradiation For Hematologic Malignancies and Bone Marrow Failure States Completed NCT00002809 Phase 2 cyclophosphamide;methotrexate;tacrolimus
45 A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin, as Graft-versus-Host Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation Completed NCT00589563 Phase 2 cyclophosphamide;etoposide;fludarabine phosphate;melphalan;methotrexate;sirolimus;tacrolimus
46 A Phase II Study of and Oral Histone Deacytylase Inhibitor, MS-275 (NSC 706995), in Combination With Sargramostim (GM-CSF, Berlex, Inc.) Treating Relapsed and Refractory Myeloid Malignancies Completed NCT00462605 Phase 2 entinostat;sargramostim
47 A Phase II Trial of Combination Therapy With Thalidomide, Arsenic Trioxide, Dexamethasone, and Ascorbic Acid (TADA) in Patients With Chronic Idiopathic Myelofibrosis or Overlap Myelodysplastic/Myeloproliferative Disorders Completed NCT00274820 Phase 2 arsenic trioxide;dexamethasone;thalidomide
48 Pentostatin and Donor Lymphocyte Infusion for Low Donor T-cell Chimerism After Hematopoietic Cell Transplantation - A Multi-center Trial Completed NCT00096161 Phase 2 Cyclosporine;Mycophenolate Mofetil;Pentostatin
49 Phase II Study of Fludarabine, Carboplatin, and Topotecan With Thalidomide for Patients With Relapsed/Refractory or High Risk Acute Myelogenous Leukemia, Chronic Myeloid Leukemia and Advanced Myelodysplastic Syndromes Completed NCT00053287 Phase 2 carboplatin;fludarabine phosphate;thalidomide;topotecan hydrochloride
50 A Phase II Study of Reduced Intensity Allogeneic Bone Marrow Transplant for the Treatment of Myelodysplastic Syndromes Completed NCT00045305 Phase 2 Cyclosporine;Methotrexate;Photopheresis;Mycofenolate mofetil;Pentostatin

Search NIH Clinical Center for Myelodysplastic/myeloproliferative Neoplasm

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Myelodysplastic/myeloproliferative Neoplasm cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Myelodysplastic/myeloproliferative Neoplasm:
NiCord, umbilical cord blood-derived stem/progenitor cells for hemotological diseases
Embryonic/Adult Cultured Cells Related to Myelodysplastic/myeloproliferative Neoplasm:
Umbilical cord blood-derived stem cells (NiCord) PMIDs: 22198152

Cochrane evidence based reviews: myelodysplastic-myeloproliferative diseases

Sources

Genetic Tests for Myelodysplastic/myeloproliferative Neoplasm

About this section
Sources

Anatomical Context for Myelodysplastic/myeloproliferative Neoplasm

About this section

MalaCards organs/tissues related to Myelodysplastic/myeloproliferative Neoplasm:

40
Bone Marrow, Bone, Myeloid, T Cells, Liver, Endothelial, Spleen
Sources

Publications for Myelodysplastic/myeloproliferative Neoplasm

About this section

Articles related to Myelodysplastic/myeloproliferative Neoplasm:

(show top 50) (show all 120)
# Title Authors PMID Year
1
Extramedullary myelodysplastic/myeloproliferative neoplasm (MDS/MPN) with ring sideroblasts and thrombocytosis. 61
33586865 2021
2
JAK2/CALR/SF3B1 triple-mutated myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis evolving to myelofibrosis and SF3B1 single-mutated acute myeloid leukemia: Evidence of a pre-JAK2 clone. 61
33373831 2021
3
NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity? 61
33255988 2020
4
[Spontaneous remission of cutaneous myeloid sarcoma]. 61
32854968 2020
5
Acute myeloid leukemia with myelodysplasia-related changes diagnosed with multilineage dysplasia alone demonstrates a superior clinical outcome. 61
32798550 2020
6
Update on CML-Like Disorders. 61
32862848 2020
7
A case of successful acyclovir desensitization in a bone marrow transplant patient. 61
32955996 2020
8
Successful prevention of severe allergic transfusion reactions with omalizumab. 61
32134497 2020
9
RAS Pathway Mutation Patterns in Patients With Juvenile Myelomonocytic Leukemia: A Developing Country Single-center Experience. 61
32209330 2020
10
Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment. 61
31776464 2020
11
Juvenile myelomonocytic leukemia - A bona fide RASopathy syndrome. 61
32460983 2020
12
Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a "catch-all" term? 61
32460977 2020
13
Myelodysplastic/myeloproliferative neoplasms: are morphology and immunophenotyping still relevant? 61
32460987 2020
14
A Rare Case of Systemic Mastocytosis with Associated Hematologic Neoplasm (SM-AHN) Involving Chronic Myeloid Leukemia: A Case Report and Literature Review. 61
32398637 2020
15
Genetic Factors in Acute Myeloid Leukemia With Myelodysplasia-Related Changes. 61
31977035 2020
16
Concurrent JAK2 V617F and MPL W515L in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. 61
31750750 2020
17
Distinguishing atypical chronic myeloid leukemia from other Philadelphia-negative chronic myeloproliferative neoplasms. 61
31904665 2020
18
Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. 61
31511613 2020
19
Efficacy of ruxolitinib in a patient with myelodysplastic/myeloproliferative neoplasm unclassifiable and co-mutated JAK2, SF3B1 and TP53. 61
33194542 2020
20
CircRNAs Dysregulated in Juvenile Myelomonocytic Leukemia: CircMCTP1 Stands Out. 61
33490078 2020
21
Single-Center Experience With Epigenetic Treatment for Juvenile Myelomonocytic Leukemia. 61
32328464 2020
22
Myelodysplastic/myeloproliferative neoplasm with eosinophilia as a manifestation of Li Fraumeni Syndrome. 61
31230491 2019
23
Lymphoblastic leukemia following myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. 61
31017498 2019
24
JAK2 exon 12 mutation in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Not an exclusive mutation to polycythaemia vera. 61
31418453 2019
25
"Bone marrow aspirate automated counts on hematology analyzers: formulating a scoring system based on hematology parameters, to discriminate reactive versus myelodysplastic syndrome-related bone marrows". 61
31102331 2019
26
Revisiting diagnostic criteria for myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Borderline cases without anemia exist. 61
30811101 2019
27
Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management". 61
30618061 2019
28
NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. 61
30902805 2019
29
Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN with RS-T) complicated by hyperleukocytosis and gene analysis in relation to leukocytosis. 61
30726782 2019
30
Chronic Neutrophilic Leukemia: Current and Future Perspectives. 61
30581159 2019
31
A Case of SF3B1-Positive Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis 61
30468430 2019
32
Molecular Cytogenetic Characterization of a Case of a Myelodysplastic/Myeloproliferative Neoplasm, Chronic Myelomonocytic Leukemia-1 (CMML-1) with Abnormal Karyotype with an Apparent Monosomy 7 Resulting in Rearrangements Involving Chromosomes 7 and 21. 61
30840601 2019
33
[Essential thrombocythemia correctly diagnosed through the guidance of comprehensive genomic profiling]. 61
31902812 2019
34
[Concurrent CALR and SF3B1 gene mutations in a patient with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis]. 61
31484889 2019
35
Gender disparity in the survival of patients with primary myelodysplastic syndrome. 61
30854142 2019
36
Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet. 61
31723789 2018
37
Hypomethylating agents (HMAs) effect on myelodysplastic/myeloproliferative neoplasm unclassifiable (MDS/MPN-U): single institution experience. 61
29465270 2018
38
Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable. 61
30242087 2018
39
Refractoriness to red blood cell transfusion therapy due to hypersplenism. 61
30260482 2018
40
Integrated molecular profiling of juvenile myelomonocytic leukemia. 61
29437595 2018
41
Sipa1 deficiency-induced bone marrow niche alterations lead to the initiation of myeloproliferative neoplasm. 61
29514790 2018
42
[Myelodysplastic/myeloproliferative neoplasm: a histopathological review]. 61
30305512 2018
43
[FGFR1-mutated B-cell acute lymphoblastic leukemia transforming to myelodysplastic / myeloproliferative neoplasm and acute myeloid leukemia]. 61
30078796 2018
44
Atypical chronic myeloid leukaemia - a rare subtype of myelodysplastic/myeloproliferative neoplasm. 61
29692658 2018
45
Evaluation by Flow Cytometry of Mature Monocyte Subpopulations for the Diagnosis and Follow-Up of Chronic Myelomonocytic Leukemia. 61
29707521 2018
46
Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia. 61
28548124 2017
47
Atypical chronic myeloid leukemia with isochromosome (X)(p10): A case report. 61
28927137 2017
48
Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. 61
28495918 2017
49
Generalized palisaded neutrophilic and granulomatous dermatitis-a cutaneous manifestation of chronic myelomonocytic leukemia? A clinical, histopathological, and molecular study of 3 cases. 61
28442268 2017
50
Bone marrow morphology and disease progression in congenital thrombocytopenia: a detailed clinicopathologic and genetic study of eight cases. 61
28059092 2017
Sources

Variations for Myelodysplastic/myeloproliferative Neoplasm

About this section
Sources

Expression for Myelodysplastic/myeloproliferative Neoplasm

About this section
Search GEO for disease gene expression data for Myelodysplastic/myeloproliferative Neoplasm.
Sources

Pathways for Myelodysplastic/myeloproliferative Neoplasm

About this section

Pathways related to Myelodysplastic/myeloproliferative Neoplasm according to KEGG:

36
# Name Kegg Source Accession
1 Ras signaling pathway hsa04014

Pathways related to Myelodysplastic/myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

(show all 49)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 63
Show member pathways
 13.8 PDGFRB NRAS NF1 JAK2 HRAS FLT3
2
Developmental Biology 65
Show member pathways
 13.46 PTPN11 PDGFRB NRAS NF1 JAK2 HRAS
3
Akt Signaling 63
Show member pathways
 13.38 PDGFRB NRAS JAK2 HRAS FLT3 CSF3R
4
PAK Pathway 63
Show member pathways
 13.27 PTPN11 PDGFRB NRAS JAK2 HRAS CSF3R
5
Cytokine Signaling in Immune system 65
Show member pathways
 13.17 PTPN11 PDGFRB NRAS NF1 JAK2 HRAS
6
PI3K-Akt signaling pathway 36
Show member pathways
 12.95 PDGFRB NRAS JAK2 HRAS FLT3 CSF3R
7
MAPK signaling pathway 36 1
12.74 PDGFRB NRAS NF1 HRAS FLT3
8
Endometrial cancer 36
Show member pathways
 12.66 PTPN11 PDGFRB NRAS HRAS FLT3 CSF2
9
T cell receptor signaling pathway 36
Show member pathways
 12.55 PTPN11 NRAS JAK2 HRAS CSF2
10
Pathways in cancer 36
12.53 PDGFRB NRAS JAK2 HRAS FLT3 CSF3R
11
Immune response IL-23 signaling pathway 23
Show member pathways
 12.52 PTPN11 PDGFRB NRAS JAK2 HRAS
12
VEGF Signaling 66
Show member pathways
 12.47 NRAS JAK2 HRAS ABL1
13
Prolactin Signaling Pathway 1 36
Show member pathways
 12.45 PTPN11 NRAS JAK2 HRAS
14
MicroRNAs in cancer 36
12.43 PDGFRB NRAS HRAS DNMT3A ABL1
15
Phospholipase D signaling pathway 36
Show member pathways
 12.38 PTPN11 PDGFRB NRAS HRAS
16
Development VEGF signaling via VEGFR2 - generic cascades 23
Show member pathways
 12.37 PTPN11 NF1 JAK2 HRAS
17
Development FGFR signaling pathway 23
Show member pathways
 12.37 PTPN11 NRAS HRAS FLT3
18
CNTF Signaling 63
Show member pathways
 12.31 NRAS JAK2 HRAS FLT3
19
Paradoxical activation of RAF signaling by kinase inactive BRAF 65
Show member pathways
 12.27 NRAS NF1 JAK2 HRAS
20
G-protein signaling Ras family GTPases in kinase cascades (scheme) 23
Show member pathways
 12.26 PTPN11 NRAS JAK2 HRAS
21
Axon guidance 36
12.21 PTPN11 NRAS HRAS ABL1
22
Ras signaling pathway 36
Show member pathways
 12.15 PTPN11 PDGFRB NRAS NF1 HRAS FLT3
23
EGF/EGFR Signaling Pathway 1
12.14 PTPN11 JAK2 HRAS ABL1
24
Development EGFR signaling via small GTPases 23
Show member pathways
 12.08 PTPN11 PDGFRB NRAS HRAS
25
Tyrosine Kinases / Adaptors 4
12.06 PDGFRB JAK2 FLT3 ABL1
26
UVA-Induced MAPK Signaling 63
Show member pathways
 12.03 NRAS JAK2 HRAS ABL1
27
JAK-STAT signaling pathway 36
Show member pathways
 12.03 PTPN11 PDGFRB JAK2 HRAS CSF3R CSF2
28
Oncogenic MAPK signaling 65
Show member pathways
 11.98 NRAS NF1 JAK2 HRAS
29
AGE-RAGE signaling pathway in diabetic complications 36
11.88 NRAS JAK2 HRAS
30
Hematopoietic cell lineage 36
11.87 FLT3 CSF3R CSF2
31
Development EPO-induced Jak-STAT pathway 23
Show member pathways
 11.86 PTPN11 JAK2 HRAS
32
MAP Kinase Signaling 4
11.85 PTPN11 NRAS NF1 HRAS
33
Glioblastoma Multiforme 63
11.82 PDGFRB NRAS NF1 HRAS
34
Gap junction 36
11.81 PDGFRB NRAS HRAS
35
Immune response IL-2 activation and signaling pathway 23
Show member pathways
 11.77 PTPN11 JAK2 HRAS
36
ErbB signaling pathway 36 1
Show member pathways
 11.72 PTPN11 PDGFRB NRAS NF1 JAK2 HRAS
37
Commom Cytokine Receptor G Chain Siganaling Pathway 66
11.71 NRAS JAK2 HRAS
38
VEGF Pathway (Tocris) 60
Show member pathways
 11.68 PDGFRB NRAS HRAS FLT3
39
Negative regulation of MAPK pathway 65
Show member pathways
 11.65 NRAS JAK2 HRAS
40
Central carbon metabolism in cancer 36
11.58 PDGFRB NRAS HRAS FLT3
41
Aryl Hydrocarbon Receptor 1
11.49 NRAS NF1 HRAS
42
Interleukin-11 Signaling Pathway 1
11.44 PTPN11 JAK2 HRAS
43
Vemurafenib Pathway, Pharmacodynamics 60
11.41 PDGFRB NRAS HRAS
44
PDGFR-beta signaling pathway 1
11.36 PTPN11 PDGFRB HRAS ABL1
45
Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics 60
11.31 PDGFRB NRAS HRAS
46
Syndecan-2-mediated signaling events 1
11.22 NF1 HRAS CSF2
47
Development_Leptin signaling via JAK/STAT and MAPK cascades 23
Show member pathways
 11.16 PTPN11 JAK2 HRAS
48
p38MAPK events 65
10.8 NRAS HRAS
49
Pilocytic astrocytoma 1
10.18 PTPN11 NF1
Sources

GO Terms for Myelodysplastic/myeloproliferative Neoplasm

About this section

Cellular components related to Myelodysplastic/myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.73 U2AF1L4 U2AF1 SRSF2 SETBP1 PTPN11 LUC7L2
2 nucleus GO:0005634 9.53 U2AF1L4 U2AF1 TET2 SRSF2 SETBP1 PTPN11
3 U2AF GO:0089701 9.16 U2AF1L4 U2AF1

Biological processes related to Myelodysplastic/myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.99 PDGFRB JAK2 HRAS FLT3 CSF2
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.81 PTPN11 PDGFRB HRAS ABL1
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.76 PTPN11 JAK2 ABL1
4 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.75 PDGFRB JAK2 FLT3
5 Ras protein signal transduction GO:0007265 9.72 NRAS NF1 HRAS
6 chromatin organization GO:0006325 9.72 TET2 KMT2A JAK2 DNMT3A ASXL1
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.71 JAK2 FLT3 CSF2
8 protein autophosphorylation GO:0046777 9.67 PDGFRB JAK2 FLT3 ABL1
9 positive regulation of MAP kinase activity GO:0043406 9.65 PDGFRB HRAS FLT3
10 mRNA 3'-end processing GO:0031124 9.63 U2AF1L4 U2AF1 SRSF2
11 dendritic cell differentiation GO:0097028 9.61 FLT3 CSF2
12 RNA export from nucleus GO:0006405 9.61 U2AF1L4 U2AF1 SRSF2
13 positive regulation of phosphoprotein phosphatase activity GO:0032516 9.6 PDGFRB JAK2
14 positive regulation of phospholipase C activity GO:0010863 9.57 PDGFRB HRAS
15 regulation of myeloid cell differentiation GO:0045637 9.56 CSF3R CSF2
16 peptidyl-tyrosine phosphorylation GO:0018108 9.56 PDGFRB JAK2 FLT3 ABL1
17 cytokine-mediated signaling pathway GO:0019221 9.55 PTPN11 JAK2 FLT3 CSF3R CSF2
18 Bergmann glial cell differentiation GO:0060020 9.52 PTPN11 ABL1
19 response to fluid shear stress GO:0034405 9.49 PDGFRB CSF2
20 platelet-derived growth factor receptor-beta signaling pathway GO:0035791 9.4 PDGFRB ABL1
21 platelet-derived growth factor receptor signaling pathway GO:0048008 9.26 PTPN11 PDGFRB JAK2 ABL1
22 MAPK cascade GO:0000165 9.17 PDGFRB NRAS NF1 JAK2 HRAS FLT3

Molecular functions related to Myelodysplastic/myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.3 U2AF1 TET2 SRSF2 SETBP1 PTPN11 PDGFRB
2 insulin receptor substrate binding GO:0043560 9.26 PTPN11 JAK2
3 peptide hormone receptor binding GO:0051428 9.16 PTPN11 JAK2
4 pre-mRNA 3'-splice site binding GO:0030628 8.96 U2AF1L4 U2AF1
5 protein tyrosine kinase activity GO:0004713 8.92 PDGFRB JAK2 FLT3 ABL1
Sources

Sources for Myelodysplastic/myeloproliferative Neoplasm

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....